Bristol Myers Squibb and SystImmune Announce Positive Phase 3 Results for Izalontamab Brengitecan in NSCLC

Bristol Myers Squibb and SystImmune reported positive interim Phase 3 PANKU-Lung01 results for izalontamab brengitecan in previously treated EGFR-mutated non-small cell lung cancer. The EGFRxHER3 antibody-drug conjugate doubled median progression-free survival compared with chemotherapy. BMS is continuing to develop the drug within its oncology portfolio, citing its potential to address unmet needs across multiple tumor types.